Publicly funded clinical trials and the future of cancer care

Oncologist

Volumn 18, Issue 2, 2013, Pages 232-238

  Schilsky, Richard L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; B RAF KINASE; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GEMCITABINE; IXABEPILONE; K RAS PROTEIN; METHOTREXATE; PACLITAXEL; PREDNISONE; RALOXIFENE; TAMOXIFEN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER THERAPY; COLON RESECTION; COLORECTAL CANCER; COOPERATION; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; FUNDING; HUMAN; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CLINICAL TRIALS AS TOPIC; FINANCING, GOVERNMENT; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; UNITED STATES;

EID: 84874361972     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0423     Document Type: Article

References (28)

1. Institute of Medicine. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI cooperative group program. Washington, DC: National Academies Press, 2010.
2. Minasian LM, Carpenter WR, Weiner BJ et al. Translating research into evidence-based practice: The National Cancer Institute Community Clinical Oncology Program. Cancer 2010;116: 4440-4449.
3. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328: 1002-1006.
4. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
5. Rugo HS, Barry WT, Moreno-Aspitia A et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2012:30(suppl): Abstr CRA1002.
6. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429-2440.
7. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
8. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
9. O'Leary M, Krailo M, Anderson JR et al. Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin Oncol 2008;35:484-493.
10. Smalley SR, Benedetti JK, Haller DG et al. Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-2333.
11. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098.
12. Peters WP, Rosner GL, Vredenburgh JJ et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005;23: 2191-2200.
13. Vogel VG, Costantino JP, Wickerham DL et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
14. Vogel VG, Costantino JP, Wickerham DL et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: Preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696-706.
15. Mittmann N, Au HJ, Tu D et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO 17 trial. J Natl Cancer Inst 2009;101:1182-1192.
16. Institute of Medicine. Initial national priorities for comparative effectiveness research. Washington, DC: National Academies Press, 2009.
17. Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004;350:2050-2059.
18. Jayne DG, Guillou PJ, Thorpe H et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol 2007;25:3061-3068.
19. Bilimoria KY, Bentrem DJ, Nelson H et al. Use and outcomes of laparoscopic-assisted colectomy for cancer in the United States. Arch Surg 2008;143: 832-839.
20. Hughes KS, Schnaper LA, Berry D et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971-977.
21. Soulos PR, Yu JB, Roberts KB et al. Assessing the impact of a cooperative group trial on breast cancer care in the Medicare population. J Clin Oncol 2012;30:1601-1607.
22. Whitman SP, Archer KJ, Feng L et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B study. Cancer Res 2001;61:7233-7239.
23. Ogino S, Meyerhardt JA, Irahara J, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009;15:7322-7329.
24. Ogino S, Shima K, Meyerhardt JA et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from Intergroup TrialCALGB89803 ClinCancerRes2012;18:890-900.
25. Venook AP, Niedzwiecki D, Lopatin M et al. Biological determinants of tumor recurrence in stage II colon cancer: Validation study of the 12-gene Recurrence Score in CALGB 9581. J Clin Onol 2013 (in press).
26. Edelman MJ, Watson D, Wang X et al. Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib chemotherapy-Cancer and Leukemia Group B trial 30203. J Clin Oncol 2008;26: 848-855.
27. Schilsky RL, Doroshow J, LeBlanc M et al. Development and use of integral assays in clinical trials. Clin Cancer Res 2012;18:1540-1546.
28. National Cancer Institute. Compressing timelines for CTEP-supported cancer treatment trials: A response to the OEWG report. Available at http://ctep.cancer.gov/SpotlightOn/OEWG.htm. Accessed January 15, 2013.